284 related articles for article (PubMed ID: 11318537)
1. Efficacy of rabeprazole once daily for acid-related disorders.
Lanza F; Bardhan KD; Perdomo C; Niecestro R; Barth J
Dig Dis Sci; 2001 Mar; 46(3):587-96. PubMed ID: 11318537
[TBL] [Abstract][Full Text] [Related]
2. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.
Cloud ML; Enas N; Humphries TJ; Bassion S
Dig Dis Sci; 1998 May; 43(5):993-1000. PubMed ID: 9590413
[TBL] [Abstract][Full Text] [Related]
3. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
Langtry HD; Markham A
Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
[TBL] [Abstract][Full Text] [Related]
4. Rabeprazole: an update of its use in acid-related disorders.
Carswell CI; Goa KL
Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
[TBL] [Abstract][Full Text] [Related]
5. The benefit/risk profile of rabeprazole, a new proton-pump inhibitor.
Johnson D; Perdomo C; Barth J; Jokubaitis L
Eur J Gastroenterol Hepatol; 2000 Jul; 12(7):799-806. PubMed ID: 10929909
[TBL] [Abstract][Full Text] [Related]
6. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Caro JJ; Salas M; Ward A
Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
[TBL] [Abstract][Full Text] [Related]
7. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group.
Thjodleifsson B; Beker JA; Dekkers C; Bjaaland T; Finnegan V; Humphries TJ
Dig Dis Sci; 2000 May; 45(5):845-53. PubMed ID: 10795744
[TBL] [Abstract][Full Text] [Related]
8. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
de Korwin JD; Ducrotté P; Vallot T
Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
[TBL] [Abstract][Full Text] [Related]
9. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.
Fitton A; Wiseman L
Drugs; 1996 Mar; 51(3):460-82. PubMed ID: 8882382
[TBL] [Abstract][Full Text] [Related]
10. Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.
Lim PW; Goh KL
J Gastroenterol Hepatol; 2004 Sep; 19 Suppl 3():S61-8. PubMed ID: 15324384
[TBL] [Abstract][Full Text] [Related]
11. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
Caos A; Breiter J; Perdomo C; Barth J
Aliment Pharmacol Ther; 2005 Aug; 22(3):193-202. PubMed ID: 16091056
[TBL] [Abstract][Full Text] [Related]
12. Rabeprazole.
Med Lett Drugs Ther; 1999 Nov; 41(1066):110-2. PubMed ID: 10987010
[No Abstract] [Full Text] [Related]
13. [A randomized, prospective, comparative, multicenter study of rabeprazole and ranitidine in the treatment of reflux esophagitis].
Jeong HY; Lee BS; Sung JK; Lee TY; Yoon SJ; Kim SJ; Chung IK; Lee SH; Shin JE; Lee DS; Baek JT; Nam SW; Yoon SJ; Kim SH; Lee GS; Lee JM; Kim AN; Oh JI
Korean J Gastroenterol; 2006 Jan; 47(1):15-21. PubMed ID: 16434864
[TBL] [Abstract][Full Text] [Related]
14. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
Dekkers CP; Beker JA; Thjodleifsson B; Gabryelewicz A; Bell NE; Humphries TJ
Aliment Pharmacol Ther; 1999 Jan; 13(1):49-57. PubMed ID: 9892879
[TBL] [Abstract][Full Text] [Related]
15. [Pharma-clinics medication of the month. Rabeprazole (Pariet)].
Louis E
Rev Med Liege; 2002 Jan; 57(1):53-6. PubMed ID: 11899500
[TBL] [Abstract][Full Text] [Related]
16. Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease.
Delchier JC; Cohen G; Humphries TJ
Scand J Gastroenterol; 2000 Dec; 35(12):1245-50. PubMed ID: 11199361
[TBL] [Abstract][Full Text] [Related]
17. [Comparative study of proton pump inhibitors].
Herszényi L; Tulassay Z
Orv Hetil; 2001 Sep; 142(36):1953-61. PubMed ID: 11680100
[TBL] [Abstract][Full Text] [Related]
18. CYP2C19 genotype and the PPIs--focus on rabeprazole.
Lim PW; Goh KL; Wong BC
J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S22-8. PubMed ID: 16359346
[TBL] [Abstract][Full Text] [Related]
19. [Proton-pump inhibitor Rabeprazole: faster acid- and symptom-control].
Dtsch Med Wochenschr; 1998 Nov; 123(47 Suppl):1-4. PubMed ID: 9856116
[No Abstract] [Full Text] [Related]
20. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group.
Caos A; Moskovitz M; Dayal Y; Perdomo C; Niecestro R; Barth J
Am J Gastroenterol; 2000 Nov; 95(11):3081-8. PubMed ID: 11095321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
